CEO of cell therapy firm Stempeutics BN Manohar speaks to Scrip about partnering with Japanese firms for India’s first allogenic cell therapy Stempeucel. Amid a tough funding environment, AI and new manufacturing tech will drive savings as the company pursues new indications and changes in Indian regulation on clinical trials could make the CGT journey easier, he says in the interview.
Stempeutics CEO BN Manohar Speaks To Scrip
Stempeutics Research Pvt. Ltd. commercialized India’s first allogenic stem cell therapy Stempeucel after the Drugs Controller General of India granted manufacturing and marketing approval for treatment of Critical Limb Ischemia (CLI) due to Buerger’s disease and CLI due to atherosclerotic peripheral arterial disease.
The Mesenchymal Stromal Cells (MSCs) product was later also approved in India to treat knee osteoarthritis (OA) and diabetic foot...
Keep up with the top pharma business news of the week. On the go.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.